TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33885718
Drug: Single-agent Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent Carboplatin every 3 weeks
Study: 33885718
Drug: Weekly Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly Carboplatin plus Paclitaxel
Study: 32355108
Drug: Extragenital screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extragenital screening at both sites (rectal and pharyngeal)
Study: 32355108
Drug: Extragenital screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extragenital screening only at the rectal site
Study: 32355108
Drug: Increasing only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing only rectal screening
Study: 33682378
Drug: Ixekizumab (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (continued treatment every 2 weeks)
Study: 33682378
Drug: Placebo (withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (withdrawal of ixekizumab treatment every 2 weeks)
Study: 33682378
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with ixekizumab after relapse
Study: 35282441
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg) three times a day plus phentermine hydrochloride (37.5 mg) once daily
Study: 35282441
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day plus phentermine hydrochloride (37.5 mg) once daily
Study: 36375977
Drug: pemafibrate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate (0.4 mg orally per day)
Study: 36375977
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acid ethyl esters (4 g orally per day)
Study: 35490744
Drug: Lenabasum 20
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenabasum 20 mg daily for 28 days, then 20 mg BID for 56 days
Study: 33346856
Drug: Patient concerns
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient concerns inventory (PCI) intervention used in outpatient clinics for one year after treatment.
Study: 32307012
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg NaHCO3 solution
Study: 33884909
Drug: Meldonium trials
Normalized name: meldonium
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium trials (details on dosage and duration not available)
Study: 32542023
Drug: Proton-pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitors (PPIs)
Study: 36531558
Drug: Isoflavone 50
Normalized name: soy isoflavone 50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone 50 mg daily for three months
Study: 36531558
Drug: Isoflavone 50
Normalized name: soy isoflavone 50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone 50 mg daily
Study: 33082191
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 10 mg/kg/day
Study: 33082191
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 15 mg/kg/day
Study: 34453416
Drug: Generic tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic tadalafil tablet (10 mg)
Study: 34453416
Drug: Marketed tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed tadalafil tablet (10 mg)
Study: 32979645
Drug: Locoregional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatments (LRTs)
Study: 32979645
Drug: Locoregional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatments (LRTs) after first progression
Study: 34579131
Drug: Sodium Selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium Selenite Injection (SE)
Study: 32252544
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Stimulation Therapy (iCST), 14 sessions of 45 minutes each
Study: 35426326
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) treatment
Study: 36152268
Drug: anti-HBc level
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HBc level < 325 IU/ml
Study: 36152268
Drug: anti-HBc level
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HBc level ≥ 325 IU/ml
Study: 36152268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-HBc < 325 IU/ml with HBsAg >3008 IU/mL
Study: 36152268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-HBc < 325 IU/ml with HBcrAg ≥1790 U/ml
Study: 34256459
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for pancreatic cancer with liver metastasis
Study: 34256459
Drug: Systematic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic chemotherapy (current standard treatment)
Study: 33274479
Drug: CsA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA plus steroids
Study: 34629379
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium hydrate 0.1% (NSAID group) applied twice a day
Study: 35070287
Drug: Protein supplements
Normalized name: PROTEIN SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplements (20 g of protein daily)
Study: 35070287
Drug: Placebo (zero
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (zero protein supplements)
Study: 33706847
Drug: High-intensity cognitive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity cognitive behavioural therapy (CBT) only
Study: 36736921
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy
Study: 34052386
Drug: Perioperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative oral pregabalin (Lyrica, twice daily starting the evening before surgery, for a total of 4 doses)
Study: 34052386
Drug: Single‐shot interscalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐shot interscalene brachial plexus block (ISBPB, 20 ml of bupivacaine 0.25%)
Study: 34052386
Drug: Perioperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative oral pregabalin
Study: 32811236
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of neoadjuvant chemotherapy (NACT)
Study: 32811236
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of neoadjuvant chemotherapy (NACT)
Study: 32930131
Drug: Conventional concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional concurrent chemo-radiotherapy (CCRT) - 66 Gy/33 fractions/6.5 weeks
Study: 35938258
Drug: Levodopa/carbidopa 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 100/25 mg three times per day for 80 weeks (early-start)
Study: 35938258
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 40 weeks followed by levodopa/carbidopa 100/25 mg three times per day for 40 weeks (delayed-start)
Study: 35938258
Drug: Early-start treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-start treatment
Study: 35938258
Drug: Delayed-start treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-start treatment
Study: 33992441
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of CYD‐TDV and bivalent HPV vaccine
Study: 33992441
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of CYD‐TDV and bivalent HPV vaccine
Study: 32594370
Drug: Low-dose RTX
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RTX (Protocol 1, one dose of RTX 375 mg/m2)
Study: 32594370
Drug: Standard RTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard RTX protocol (Protocol 2, four weekly doses of rituximab 375 mg/m2)
Study: 33621109
Drug: Lenalidomide oral
Normalized name: lenalidomide Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide oral 15 mg/d, days 1‐14/21 plus standard R‐CHOP21
Study: 32192317
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy alone
Study: 35346499
Drug: Aspirin-Cinnamon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-Cinnamon
Study: 33651438
Drug: GLP‐1RA exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1RA exenatide once‐weekly (ExQW) for 36 weeks
Study: 33436031
Drug: Clear presentation
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear presentation of medical and surgical treatment options.
Study: 34756787
Drug: Roxadustat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat treatment for 12 weeks
Study: 33158422
Drug: Standard healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard healthy life prescription (PVS)
Study: 34293955
Drug: Active phase
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active phase with smart insulin pen cap (alarms/reminders)
Study: 35236652
Drug: Chemotherapy (Control)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Control)
Study: 32737670
Drug: Mindfulness-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based treatment targeting emotion regulation problems over 16 weeks
Study: 32394851
Drug: Perindopril, indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril, indapamide SR, and metformin (n=40)
Study: 32394851
Drug: Perindopril, moxonidin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril, moxonidin, and metformin (n=40)
Study: 35343796
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (Bifidobacterium lactis Probio-M8, atorvastatin, metoprolol)
Study: 35343796
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (placebo, atorvastatin, metoprolol)
Study: 35228291
Drug: Prophylactic anticoagulation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anticoagulation (rivaroxaban 10 mg once a day for 3 months)
Study: 35228291
Drug: Therapeutic anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic anticoagulation (rivaroxaban 20 mg once a day for 3 months)
Study: 33839979
Drug: Postoperative Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX
Study: 33792511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (waiting for treatment)
Study: 34719399
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide monohydrate (MOMH) 226 mg, once daily at bedtime for 60 days
Study: 34719399
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily at bedtime for 60 days
Study: 35020101
Drug: Topical nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nalbuphine 2 mg/ml (Group A)
Study: 35020101
Drug: Topical nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nalbuphine 1 mg/ml (Group B)
Study: 35020101
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tears (Group C)
Study: 34933333
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 on days 1 through 7 with durvalumab 1500 mg on day 1 every 4 weeks (Arm A)
Study: 34933333
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 on days 1 through 7 without durvalumab (Arm B)
Study: 33729467
Drug: nCT (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCT (neoadjuvant chemotherapy) followed by minimally invasive esophagectomy (MIE)
Study: 33515267
Drug: Non-nicotinic e-cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-nicotinic e-cigarettes with 4 mg nicotine lozenge (ENL)
Study: 33515267
Drug: Non-nicotinic e-cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-nicotinic e-cigarettes with placebo lozenges (EPL)
Study: 32769965
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy (SC)
Study: 34981580
Drug: Red Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Light (RL) therapy
Study: 34981580
Drug: Blue Light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue Light (BL) therapy
Study: 35121105
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin Gammanorm® via pump
Study: 35121105
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin Gammanorm® via rapid push
Study: 35121105
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin Gammanorm® via pump and rapid push
Study: 33773207
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg) with methotrexate (7.5 mg/week)
Study: 33773207
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with methotrexate (7.5 mg/week)
Study: 33389108
Drug: TAU (Treatment-As-Usual)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (Treatment-As-Usual)
Study: 32022483
Drug: Mometasone furoate-formoterol
Normalized name: mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate-formoterol (MF/F) 100/10 µg
Study: 32022483
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 100 µg
Study: 35583988
Drug: Group logotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group logotherapy (10 weekly 2-hour sessions)
Study: 32777998
Drug: L-theanine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine 400 mg
Study: 36263942
Drug: L-theanine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine 100 mg
Study: 36263942
Drug: L-theanine 200
Normalized name: L-theanine 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine 200 mg
Study: 34816597
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) insulin delivery 24/7
Study: 34816597
Drug: Evening and
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening and night (E/N) hybrid closed-loop insulin delivery
Study: 34805194
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo injections (two per day on day 1 and 2 post-surgery) along with treatment as usual (patient-controlled morphine pump)
Study: 34805194
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (patient-controlled morphine pump)
Study: 34805194
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo injections
Study: 35618537
Drug: Advanced regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced regional analgesic techniques
Study: 35618537
Drug: Basic analgesics
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic analgesics (paracetamol, NSAIDs, cyclooxygenase-2 inhibitors, dexamethasone, local infiltration analgesia)
Study: 32938572
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire assessing knowledge, attitude, and practice regarding emergency management of TDI.
Study: 32938572
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire assessing perceived knowledge level.
Study: 32248707
Drug: Polynucleotide (PN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polynucleotide (PN) filler injection
Study: 32248707
Drug: Non-crosslinked hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-crosslinked hyaluronic acid (HA) filler injection
Study: 35807110
Drug: Bilateral QLBs-LSAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral QLBs-LSAL with 0.375% ropivacaine (20 mL each side)
Study: 39259241
Drug: Control Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Condition (CC)
Study: 35240291
Drug: Resveratrol 200
Normalized name: resveratrol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 200 mg once daily for 24 weeks
Study: 35240291
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose capsules)
Study: 35867532
Drug: Adjuvant hypnotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hypnotherapy plus conventional therapy
Study: 35279171
Drug: Anaemia screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaemia screening and treatment (anaemia arm)
Study: 33087250
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin D3 (540,000 IU)
Study: 35656394
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment
Study: 33122344
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × N-AVD (doxorubicin, vinblastine, dacarbazine with two concomitant nivolumab infusions per cycle)
Study: 33153707
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C
Study: 32301501
Drug: GSK2982772, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772, 60 mg twice daily (b.i.d.)
Study: 32301501
Drug: GSK2982772, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772, 60 mg three times daily (t.i.d.)
Study: 34320288
Drug: CMV hyperimmune
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV hyperimmune globulin (100 mg/kg monthly until delivery)
Study: 32528568
Drug: Enoxaparin-warfarin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin-warfarin
Study: 34024233
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 10 mg/kg infusion in 100 mL normal saline
Study: 34024233
Drug: Placebo (distilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (distilled water in 100 mL normal saline)
Study: 33099848
Drug: IDegAsp (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegAsp (twice-daily single injection)
Study: 33099848
Drug: IDeg +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg + Lira (once-daily dual injection)
Study: 32521096
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Study: 32246743
Drug: Rivaroxaban (bodyweight-adjusted,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (bodyweight-adjusted, administered once-daily, twice-daily, or thrice-daily)
Study: 32246743
Drug: Rivaroxaban (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (tablet and suspension formulation)
Study: 36200921
Drug: HA-filler serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-filler serum (applied starting 24 hours after BoNTA injection, then twice daily for 24 weeks)
Study: 34857525
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg daily in two divided doses for adults or 2 mg/kg/day for children, escalating to 4 mg/kg/day if no side effects are encountered, for a total of 12 months for adults and 6 months for children.
Study: 33293274
Drug: LDL-C concentrations
Normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C concentrations <1.8 mmol/L (<70 mg/dL; 1st-5th centiles)
Study: 33293274
Drug: LDL-C concentrations
Normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C concentrations >4.8 mmol/L (>189 mg/dL; 96th-100th centiles)
Study: 33293274
Drug: LDL-C concentration
Normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C concentration of 3.6 mmol/L (140 mg/dL)
Study: 33293274
Drug: LDL-C concentration
Normalized name: PROTEIN C CONCENTRATE
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C concentration of 2.3 mmol/L (89 mg/dL)
Study: 32905611
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - bolus dose of 10 mg kg−1 followed by 8 hours continuous infusion of 3 mg kg−1 h−1